Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Affymax, Inc. To Contact The Firm
NEW YORK, March 1, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Affymax, Inc. ("Affymax" or the "Company") (NASDAQ: AFFY).
(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) 2% of patients taking Affymax's kidney treatment drug Omontys were experiencing hypersensitivity reactions resulting in anaphylaxis, a serious and life-threatening allergic reaction; and (2) 0.02% of those taking Omontys experienced fatal anaphylaxis reactions.
On February 23, 2013, Affymax announced that the U.S. Food and Drug Administration ("FDA") was requiring a total recall of the drug due to reports of anaphylaxis. According to the FDA, "serious and fatal" hypersensitivity reactions had been reported in some patients within 30 minutes of receiving their first doses of the drug by intravenous injection. On this news, the price of Affymax stock declined by more than 85%, closing at $2.42 per share, down $14.10 per share from the prior night's close.
Request more information now by clicking here: www.faruqilaw.com/AFFY. There is no cost or obligation to you.
Take Action
If you invested in Affymax stock or options between December 8, 2011 and February 22, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/AFFY. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Affymax's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP
RELATED LINKS
http://www.faruqilaw.com
More by this Source
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Poseidon Concepts Corp. To Contact The Firm
Mar 01, 2013, 21:09 ET
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Accretive Health, Inc. To Contact The Firm
Mar 01, 2013, 21:09 ET
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Avid Technology, Inc. To Contact The Firm
Mar 01, 2013, 21:09 ET
Featured Video
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.






